Please ensure Javascript is enabled for purposes of website accessibility

Is iShares Nasdaq Biotechnology Index Fund a Buy?

By Nicholas Rossolillo – Updated Apr 12, 2019 at 1:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The largest biotech ETF looks good for investors who don't mind the industry's manic behavior.

The biotechnology industry is one of the most hazardous places for stock pickers. Volatility is high, even among the largest companies. Creating new compounds and processes that solve complicated medical problems is not an easy business, and there's frequent failure to get viable new products to market.

Often times, the adage "it's better to be lucky than talented" applies to a biotech's development pipeline. The same can also be said for investors trying to pick big winners from the biotech universe too, which harkens back to a familiar Warren Buffett quote: "Risk comes from not knowing what you're doing."

Test tubes

Image Source: Getty Images

For investors who don't know ins-and-outs of biotech (like myself), picking individual stocks can be dangerous. That's where an ETF comes in, like the biggest biotech ETF out there: the iShares Nasdaq Biotechnology Fund (IBB 0.06%).

Here's how it stacks up next to its peers SPDR S&P Biotech ETF (XBI 0.94%) and First Trust NYSE Arca Biotech ETF (FBT 0.10%)


iShares Nasdaq Biotechnology Fund 

SPDR S&P Biotech ETF 

First Trust NYSE Arca Biotech ETF 

Fund total net assets

$8.03 billion

$4.12 billion

$2.87 billion

Number of stocks




Date of inception

Feb. 5, 2001

Jan. 31, 2006

June 19, 2006

Annual expense ratio




Dividend yield




Data source: iShares, SPDR, and First Trust.  

The iShares option is the oldest, largest, and most diverse biotech ETF available, and its expense ratio is industry standard.

It's worth noting over the last decade iShares has lagged behind its competition because of the composition of the fund; iShares weights its holdings by market capitalization. This means the bigger companies drive overall returns, and since those top five holdings have been a mixed bag over the last few years, the fund has also lagged.  

Meanwhile, SPDR Biotech and First Trust Biotech ETFs are both equal weighted, with each stock receiving equal representation in the fund. Smaller winners have meant greater returns for these funds, although with more profit comes greater tax implications when the funds are rebalanced. 

IBB Chart

Data by YCharts.

Check out the latest earnings call transcripts for the companies we cover.

First, let's look at the makeup of the big-player driven fund:

Top Five Holdings From iShares Nasdaq Biotechnology Fund 


Celgene (CELG)


Biogen (BIIB 0.48%)


Amgen (AMGN -0.45%)


Gilead Sciences (GILD 0.20%)


Illumina (ILMN -0.77%)


Holdings as of March 6, 2019. Data source: iShares.  

Next, see how smaller companies, which are often takeover targets, drive the growth of the SPDR fund:

Top Five Holdings From SPDR S&P Biotech ETF 


Spark Therapeutics (ONCE)


Puma Biotechnology (PBYI 6.33%)


Portola Pharmaceuticals (PTLA)


Sage Therapeutics (SAGE 0.22%)


Mirati Therapeutics (MRTX -3.76%)


Holdings as of March 6, 2019. Data source: SPDR.  

And First Trust Biotech too:

Top Five Holdings From First Trust NYSE Arca Biotech ETF 


ACADIA Pharmaceuticals (ACAD 0.77%)


Ionis Pharmaceuticals (IONS -0.28%)


Ultragenyx Pharmaceutical (RARE 0.09%)


Bio-Techne Corporation (TECH 1.19%)


Charles River Laboratories (CRL 0.02%)


Holdings as of March 6, 2019. Data source: First Trust.  

Is it a buy?

Biotechnology is a unique growth industry, but the risks are higher than average. For those without the technical know-how and the stomach for some wild moves -- even when well-diversified -- the iShares Nasdaq Biotechnology Fund is a solid choice. It offers lower overall returns than some of its peers due to the overweighting toward the biggest players in the space, but it has also exhibited the lowest volatility over time. That could make this one of the tamest pure-play bets on the wild sector.

For broader exposure to healthcare, there's also the Vanguard Health Care ETF (VHT 0.56%), which has 385 stocks, and 20% of its assets are dedicated specifically to biotech. It has a management fee of just 0.10% a year and is far less volatile than the biotech pure plays because it also includes the more stable segments of the healthcare universe. 

Nevertheless, for those who want targeted exposure to biotech, the iShares Nasdaq Biotechnology Fund is a good option. The management fee is reasonable, and there's plenty of diversification to smooth out a few of the hang-ups that can be problematic with investing in individual biotech stocks.


Nicholas Rossolillo and his clients own shares of Gilead Sciences and Vanguard Health Care ETF. The Motley Fool owns shares of and recommends Biogen, Celgene, Gilead Sciences, Illumina, and Ionis Pharmaceuticals. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.